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INTRODUCTION 
Oral route is the easiest and most convenient route for non 
invasive drug administration. Oral drug delivery systems 
being the most cost-effective have been leading the worldwide 
in the drug delivery market. Numerous potent lipophilic drugs 
exhibit low oral bioavailability due to their poor aqueous 
solubility properties. Efforts are ongoing to enhance the oral 
bioavailability of lipophilic drugs in order to increase their 
clinical efficacy. The most popular approach is the 
incorporation of the active lipophilic component into inert 
lipid vehicles, such as oils, surfactant dispersions, self-
emulsifying formulations, emulsions   and liposomes, with 
every formulation approach having its special advantages and 
limitations. 
Efficacy of lipophilic drug is often hindered due to their poor 
aqueous solubility leading to low absorption after in vivo 
administration. A part of the administered dose is absorbed 
and reaches the pharmacological site of action and remainder 
causes toxicity and undesirable side effects due to unwanted 
bio-distribution. Enhancement in drug efficacy and lowering 
of drug toxicity could be achieved through encapsulation and 
delivery of the drug in lipid based delivery system. 
The concept of drug delivery system has emerged to minimize 
the toxic side effects of drug, to broaden their application, to 
expand modes of their administration and to solve absorption 
problems. The twentieth century has witnessed a remarkable 
growth in drug development and the newly developed drugs 
are mostly lipophilic compound with poor aqueous solubility, 
which limits their efficacy and bioavailability. Solubilization, 
encapsulation, and delivery of these drugs using lipid based 
and biocompatible systems are likely to furnish better 
absorption, by way of lower dose, reduced frequency of 
administration, and improved therapeutic index. 
Over recent years, much attention has been focused on lipid 
microemulsion formulations, with particular emphasis on 
liquid self-microemulsifying and self-emulsifying drug 
delivery systems (SEDDS) to improve the oral bioavailability 
of poorly water-soluble drugs1, 2, 3. However, these delivery 
systems had a few limitations, such as stability, the 
manufacturing methods, the interaction between the filling and 
the capsule shell, and the storage temperature4. When the 
product is kept at lower temperatures, there may be some 
precipitation of the active ingredient and/or the excipients. 
Therefore, the precipitated materials should be dissolved again 
when warmed to room temperature or the drug will not be 
present in solution or as a fine emulsion droplet3. Moreover, 
its efficiency is dependent upon a moist environment5.Thus 
solid self microemulsifying drug delivery system (S-
SMEDDS) should be carefully explored as a means of 
overcoming these problems. 
NEED OF S-SMEDDS 
 S-SMEDDS, one of the lipid-based drug delivery systems 
prepared by the incorporation of liquid excipients into 
powders by solidification, is a promising drug delivery system 
for poorly water soluble compounds as it combines the 
advantages of liquid SMEDDS (solubility and bioavailability 
enhancement) with those of solid dosage forms (high stability 
with various dosage forms options) 6, 7. S-SMEDDS produce 
oil-in-water microemulsions with droplet sizes of less than 
200 nm upon mild agitation in aqueous media (such as 
gastrointestinal fluids) 7, 8. These fine microemulsion droplets 
have the advantage of presenting the drug in a dissolved form 
with a large interfacial surface area for drug absorption, which 
results in an enhanced and more uniform and reproducible 
bioavailability9. 
SMEDDS are usually, however, limited to liquid dosage 
forms, because many excipients used in SMEDDS are not 
solids at room temperature. Given the advantages of solid 
dosage forms, S-SMEDDS have been extensively exploited in 
recent years, as they frequently represent more effective 
alternatives to conventional liquid SMEDDS. From the 
perspective of dosage forms, S-SMEDDS mean solid dosage 
forms with self-emulsification properties. S-SMEDDS focus 
ABSTRACT 
Oral route still remains the favorite route of drug administration in many diseases and till today it is the first way investigated in 
the development of new dosage forms. The major problem in oral drug formulations is low and erratic bioavailability, which 
mainly results from poor aqueous solubility. As a consequence of modern drug discovery techniques, there has been a steady 
increase in the number of new pharmacologically active lipophilic compounds that are poorly water soluble. It is a great chal lenge 
for pharmaceutical scientist to convert those molecules into orally administered formulation with sufficient bioavailability. Among 
the several approaches to improve oral bioavailability of these molecules, self-micron emulsifying drug delivery system 
(SMEDDS) is one of the approaches usually used to improve the bioavailability of lipophillic drugs. However, conventional 
SMEDDS are mostly prepared in a liquid form, which can have some disadvantages. Hence, solid SMEDDS (S-SMEDDS) 
prepared by solidification of liquid/semisolid self-micron emulsifying ingredients into powders, have gained popularity. This 
article gives an overview of the recent advances in the study of S-SMEDDS, especially the related solidification techniques and the 
development of solid self-micron emulsifying dosage forms. Finally, the existing problems and the possible future research 
directions in this field are pointed out. Thus S-SMEDDS could be used as an effective oral solid dosage form to improve the 
bioavailability of hydrophobic drugs. 
Keywords: solid SMEDDS, self emulsification, solubility enhancement, bioavailability, lipophilic 
 
Bhavna et al                                        Journal of Drug Delivery & Therapeutics; 2013, 3(3), 168-174   2 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
on the incorporation of liquid/semisolid self micron 
emulsifying ingredients into powders/nanoparticles by 
different solidification techniques (e.g. adsorptions to solid 
carriers, spray drying, melt extrusion, nanoparticles 
technology, and so on). Such powders/nanoparticles, which 
refer to self emulsifying  nanoparticles10, dry emulsions/solid 
dispersions, are usually further processed into other solid SE 
dosage forms, or, alternatively, filled into capsules (i.e. self 
micro emulsifying capsules). Self micro emulsifying capsules 
also include those capsules into which liquid/semisolid 
SMEDDS are directly filled without any solidifying 
excipients. To some extent, S-SMEDDS are combinations of 
SMEDDS and solid dosage forms, so many properties of S-
SMEDDS (e.g. excipients selection, specificity, and 
characterization) are the sum of the corresponding properties 
of both SMEDDS and solid dosage forms. For instance, the 
characterizations of self micron emulsifying pellets contain 
not only the assessment of self-emulsification, but also 
friability, surface roughness, and so on. In the 1990s, S-
SMEDDS were usually in the form of self micron emulsifying 
capsules, self micron emulsifying solid dispersions and dry 
emulsions, but other solid self micron emulsifying dosage 
forms have emerged in recent years, such as self micron 
emulsifying pellets/tablets, self micron emulsifying 
microspheres/nanoparticles and self micron emulsifying 
suppositories/implants. 
ADVANTAGES OF S-SMEDDS
12, 13
 
 Low production cost 
 Convenience of process control 
 High stability and reproducibility 
 Better patient compliance 
 Spontaneous formation 
 Thermodynamic stability and 
 Improved solubilization of bioactive materials 
 More consistent temporal profiles of drug absorption 
 less drug need to be used 
 For many drugs taken by mouth 
 Faster release rates and it improve the drug acceptance by 
consumers 
 Selective drug targeting toward a specific absorption 
window in the GI tract and 
 Drug protection from the hostile environment in the gut 
 Thus, for lipophilic drug compounds that exhibit 
dissolution rate limited absorption 
 These systems may offer an improvement in the rate and 
extent of absorption and result in more reproducible blood 
time profiles 
 This may lower cost. 
 S-SMEDDS OVERCOMING THE NEED OF LIQUID 
SMEDDS
14
 
 S-SMEDDS form is more preferred than liquid SMEDDS 
form. 
 S-SMEDDS (solid microemulsion preconcentrate) readily 
forms microemulsion when comes in contact with water. 
 Need for outsourcing of soft gelatin capsule 
manufacturing at the early stage of drug product 
development may be avoided. 
 S-SMEDDS remain solid at room temperature, yet 
maintains all the advantages of liquid SMEDDS. 
 S-SMEDDS can be filled into hard gelatin capsules. 
 S-SMEDDS is highly stable and reproducible than liquid 
SMEDDS. 
 S-SMEDDS may even be incorporated into other solid 
dosage forms (e.g., fast dissolving tablets, films etc. 
ADVANTAGES OF S-SMEDDS OVER EMULSION: 
Microemulsions help in the improvement of 
drug bioavailability, protection against enzymatic hydrolysis 
and decrease toxicity. The only problem with microemulsion 
is poor palatability and moreover due to their water content, 
microemulsions cannot be encapsulated in soft and hard 
gelatin11. Hence, there is a need for delivery of lipophillic drug 
in S-SMEDDS. 
FORMULATION OF S-SMEDDS 
Formulation components of S-SMEDDS include 
 Drug 
 Oil 
 Surfactants/ cosurfactants  
 Co solvents  
 Consistency builders  
 Enzyme inhibitors   
 Adsorbents/solidifying agents 
The selection of oil, surfactant and co solvent is based on the 
solubility of the drug and preparation of the phase diagram. 
Selection of components for S-SMEDDS 
 The crucial challenges to any oral formulation design 
program is maintaining drug solubility within the 
gastrointestinal tract and, in particular, maximizing drug 
solubility within the primary absorptive site of the gut16. 
 Lipid based formulations offer a potential platform for 
improving oral bioavailability of drugs especially those 
belonging to biopharmaceutical Classification System 
(BCS) class II and class IV.  
Class II drugs are poorly water soluble drugs with high 
permeability but once they are dissolved; they absorbed over 
the gastro- intestinal membrane, and Class IV compounds are 
poorly soluble with poor permeability, respectively 17. The 
basic criteria for selection of components of lipid formulation 
are; the lipophilicity of the drug, with solubility in 
pharmaceutically-acceptable lipid excipients which should be 
sufficient to allow the entire dose of the drug to be 
administered in a single dosage unit. 
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Table: 1 Formulation components of S-SMEDDS11, 15 
s.no. Components Examples 
1 
 
 
 
 
 
Oils LCTs MCTs Fatty Acids Mono-/di-
glycerides   
Olive oil 
Corn oil 
Soyabean oil 
Castor oil 
Miglyol 810 
Miglyol 812 
Captex 255 
Captex 300 
Oleic acid 
Palmitic acid 
Capmul MCM 
Capmul GMO      
 
2 Surfactants 
 
 
 
 
Tweens 
Spans 
Cremophore RH40 
Labrafil 1944 CS 
Labrafil M 2125  
Labrafac lipophile1349 WL 
Labrasol 
Lauroglycol 90 
Capryol 90 
Peceol 
   
3 Cosurfactants  
/Cosolvents 
Alcohols & polyols 
 
Esters 
 
Esters of 
propylene glycol 
Amides 
 
  Ethanol 
Isopropranol, butanol 
benzyl alcohol 
ethylene glycol 
propylene glycol 
butanediols  
glycerol 
pentaerythritol 
sorbitol, mannitol 
transcutol 
dimethyl isosorbide 
propylene glycol  
HPMC 
ethyl propionate tributyl 
citrate 
 acetyl triethyle citrate 
 acetyl tributyl citrate 
 ethylene oleate 
 ethyl caprylate 
 ethyl butyrate 
 triacetin 
 propylene glycol 
monoacetate 
 propylene glycol diacetate 
 ε-caprolactone 
 δ-valerolactone 
 β-butyrolactone 
Tetra hydrofuryl  
alcohol 
PEG ether 
(glycofural) 
 
2pyrrolidone 
2-piperidone 
caprolactam 
Nalkylpyrrolidone  
N-alkylpiperidone 
Nalkylcaprolactam 
dimethylacetamide  
polyvinyl 
pyrrolidone 
 
 
 
 
 
4 Consistency 
builders 
 
 
   Tragacanth 
   Cetyl alcohol  
   Stearic acid 
Beeswax 
   
5 Enzyme 
inhibitors 
 
 
Non amino acids Amino acids Peptides Complexing 
agents 
P-amino benzamidine 
FK-448  
Cosmostat mesylate 
Sodium glycocolate 
aminoboronine derivatives 
n-acetylcysteine 
 
Bacitracin 
Antipain 
 Leupeptin 
Amastatin 
EDTA 
EGTA 
1,10Phenanthroline 
Hydroxychinoline 
6 Adsorbents/ 
solidifying 
agents 
 
 
neusilin US2 
fujicalin 
cellulose 
lactose 
silicates 
   
LCT: long chain triglycerides 
MCT: medium chain triglycerides 
 
Table: 2 Biopharmaceutical classification of drugs18 
BCS classes Solubility Permeability Examples 
Class I High  High  Metoprolol, diltiazem 
Class II Low  High  Phenytoin, danazol 
Class III High  Low  Cemetidine, neomycin 
Class IV Low  Low  Taxol  
 
 Since the aim of this study is to develop an oral 
formulation, therefore, solubility of drug in oils is more 
important as the ability of SMEDDS to maintain the drug 
in solubilized form is greatly influenced by the solubility 
of the drug in oil phase. Thus solubility of drug in various 
oils (Castor oil, Olive oil, Labrafil 1944 CS, Labrafac 
lipophil WL 1349, Capmul MCM C-10 etc) was 
determined19. 
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 Among physicochemical characteristics melting point and 
dose play a major role. Low melting point and low dose 
are desirable for development of lipidic systems. Drugs 
high melting point having with low log P values (around 
2) is not suitable for S-SMEDDS. 
 Phase diagrams: 
Pseudo ternary phase diagram is used to map the optimal 
composition range for three key excipients   according to the 
resulting droplet size following self emulsification, stability 
upon dilution and viscosity. Phase diagrams are useful tools to 
determine the number and types of phases, the wt% of each 
phase and the composition of each phase at a given 
temperature and composition of the system. These diagrams 
are three-dimensional but are illustrated in two-dimensions for 
ease of drawing and interpretation. 
On the basis of the solubility study of drug, oil, surfactants, 
co-surfactants and aqueous phase were used for construction 
of phase diagram. Oil, surfactant, and co-surfactant are 
grouped in four different combinations for phase studies. 
Surfactant and co-surfactant (Smix) in each group were mixed 
in different weight ratio. These Smix ratios are chosen in 
increasing concentration of surfactant with respect to co-
surfactant and in increasing concentration of co surfactant 
with respect to surfactant for detail study of the phase diagram 
for formulation of micro emulsion. For each phase diagram, 
oil, and specific Smix ratio are mixed thoroughly in different 
weight ratio in different glass vials. Different combination of 
oils and Smix were made so those maximum ratios were 
covered for the study to delineate the boundaries of phase 
precisely formed in the phase diagrams. Pseudo-ternary phase 
diagram was developed using aqueous titration method. Slow 
titration with aqueous phase is done to each weight ratio of oil 
and Smix and visual observation is carried out for transparent 
and easily flowable o/w micro emulsion. The physical state of 
the micro emulsion was marked on a pseudo-three-component 
phase diagram with one axis representing aqueous phase, the 
other representing oil and the third representing a mixture of 
surfactant and co-surfactant at fixed weight ratios (Smix 
ratio)20.  
Effect of drug on phase diagram   
The formulation amount of drug was added to the boundary 
formulations of the self microemulsifying domain of ternary 
phase diagrams. The self-micron-emulsifying performance 
was visually assessed after infinite dilution using purified 
water19.  
Mechanism of self-emulsification: Self emulsification 
occurs, when the entropy change occurs, dispersion is greater 
than the energy required to increase the energy required to 
increase the surface area of the dispersion21. The free energy 
of conventional emulsion formation is a direct function of the 
energy required to create a new surface between the two 
phases and can be described by the equation. 
∆G=∑Nπr2ϭ 
Where: 
∆G is the free energy associated with the process (ignoring the 
free energy of mixing), 
N is the number of droplets of radius r,  
ϭ  is interfacial energy with time 
The two phases of the emulsion will tend to separate, in order 
to reduce the interfacial area and subsequently, the free energy 
of the system. Therefore, the emulsions resulting from 
aqueous dilution are stabilized by conventional emulsifying 
agents, which form a monolayer around the emulsion droplets 
and hence, reduce the interfacial energy, as well as providing a 
barrier to coalescence22. In case of self-emulsifying system, 
the free energy required to form the emulsion is either very 
low or positive or negative then, the emulsion process occurs 
spontaneously23. Emulsification require very little input 
energy, involves destabilization through contraction of local 
interfacial regions. For emulsification to occur, it is necessary 
for the interfacial structure to have no resistance to surface 
shearing24. In earlier work it was suggested that the case of 
emulsification could be associated with the ease by which 
water penetrates into the various liquid crystal or phases get 
formed on the surface of the droplet25. The addition of a binary 
mixture (oil/non-ionic surfactant) to the water results in the 
interface formation between the oil and aqueous continuous 
phases, followed by the solubilization of water within the oil 
phase owing to aqueous penetration through the interface, 
which occurs until the solubilization limit is reached close to 
the interface26. Further aqueous penetration will result in the 
formation of the dispersed liquid crystalline phase. As the 
aqueous penetration proceeds, eventually all materials close to 
the interface will be liquid crystal, the actual amount 
depending on the surfactant concentration in the binary 
mixture once formed, rapid penetration of water into the 
aqueous cores, aided by the gentle agitation of the self 
emulsification process causes interface disruption and droplet 
formation. A combination of particle size analysis and low 
frequency dielectric spectroscopy was used to examine self-
emulsifying properties of a series of Imwitor 742 (a mixture of 
mono-and diglycerides of Caprylic acids/Tween 80) systems, 
which provided evidence that the formation of the emulsion 
may be associated with liquid crystal formation, although the 
relationship was clearly complex27. The presence of the drug 
may alter the emulsion characteristics, possibly by interacting 
with the liquid crystal phase.         
DESIGN OF S-SMEDDS FORMULATION 
A series of SMEDDS formulations were prepared using 
various oil, surfactant and cosurfactant . In all the 
formulations, the level of drug was kept constant. The amount 
of SMEDDS should be such that it should solubilize the drug 
(single dose) completely. The drug was added in the mixture. 
Then the components were mixed by gentle stirring and 
mixing, and heated at 37˚C.The mixture was stored at room 
temperature until used. So, prepared SMEDDS was the 
concentrate of oil, surfactant, co-surfactant and drug. Based 
upon the above results liquid SMEDDS is optimized which are 
further converted to Solid SMEDDS (Tablet) by adsorbing it 
on to adsorbent carriers like Neusilin US2, Fujicalin etc  and 
various formulations were prepared19. 
SOLIDIFICATION TECHNIQUES FOR 
TRANSFORMING LIQUID/SEMISOLID SMEDDS TO 
S-SMEDDS 
Capsule filling with liquid and semisolid self-emulsifying 
formulations: 
Capsule filling is the simplest and the most common 
technology for the encapsulation of liquid or semisolid SE 
formulations for the oral route. For semisolid formulations, it 
is a four-step process: (i) heating of the semisolid excipient to 
at least 200C above its melting point; (ii) incorporation of the 
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active substances (with stirring); (iii) capsule filling with the 
molten mixture and (iv) cooling to room temperature. For 
liquid formulations, it involves a two-step process: filling of 
the formulation into the capsules followed by sealing of the 
body and cap of the capsule, either by banding or by 
microspray sealing28. In parallel with the advances in capsule 
technology proceeding, liquid-oros technology has been 
designed for controlled delivery of insoluble drug substances 
or peptides. This system is based on osmotic principles and is 
a liquid SME formulation system. It consists of an osmotic 
layer, which expands after coming into contact with water and 
pumps the drug formulation through an orifice in the hard or 
soft capsule29. A primary consideration in capsule filling is the 
compatibility of the excipients with the capsule shell. The 
advantages of capsule filling are simplicity of manufacturing; 
suitability for low-dose highly potent drugs and high drug 
loading (up to 50% (w/w)) potential. 
Spray drying: 
Essentially, this technique involves the preparation of a 
formulation by mixing lipids, surfactants, drug, solid carriers, 
and solubilization of the mixture before spray drying. The 
solubilized liquid formulation is then atomized into a spray of 
droplets. The droplets are introduced into a drying chamber, 
where the volatile phase (e.g. the water contained in an 
emulsion) evaporates, forming dry particles under controlled 
temperature and airflow conditions. Such particles can be 
further prepared into tablets or capsules. The atomizer, the 
temperature, the most suitable airflow pattern and the drying 
chamber design are selected according to the drying 
characteristics of the product and powder specification30. 
Adsorption to solid carriers: 
Free flowing powders may be obtained from liquid self micro-
emulsifying formulations by adsorption to solid carriers. The 
adsorption process is simple and just involves addition of the 
liquid formulation onto carriers by mixing in a blender. The 
resulting powder may then be filled directly into capsules or, 
alternatively, mixed with suitable excipients before 
compression into tablets. A significant benefit of the 
adsorption technique is good content uniformity. For an 
instance a formulation of Liquid SMEDDS was made which is 
converted to Solid SMEDDS using Malto dextrin as a solid 
carrier. SMEDDS can be adsorbed at high levels (up to 70% 
(w/w)) onto suitable carriers31. Solid carriers can be micro 
porous inorganic substances, high surface-area colloidal 
inorganic adsorbent substances, cross-linked Polymers or 
Nanoparticle adsorbents, for example, silica, silicates, 
magnesium trisilicate, magnesium hydroxide, talcum 
crospovidone, cross-linked sodium carboxymethyl cellulose 
and cross linked polymethyl methacrylate. Cross-linked 
polymers create a favorable environment to sustain drug 
dissolution and also assist in slowing down drug 
reprecipitation. Nanoparticle adsorbents comprise porous 
silicon dioxide (Sylysia 550), carbon nanotubes, carbon 
nanohorns, fullerene, charcoal and bamboo charcoal32. 
Melt granulation: 
Melt granulation is a process in which powder agglomeration 
is obtained through the addition of a binder that melts or 
softens at relatively low temperatures. As a ‘one-step’ 
operation, melt granulation offers several advantages 
compared with conventional wet granulation, since the liquid 
addition and the subsequent drying phase are omitted. 
Moreover, it is also a good alternative to the use of solvent. 
The main parameters that control the granulation process are 
impeller speed, mixing time, binder particle size, and the 
viscosity of the binder. A wide range of solid and semisolid 
lipids can be applied as meltable binders. Thereinto, 
Gelucire1, a family of vehicles derived from the mixtures of 
mono-/di-/tri-glycerides and polyethylene glycols (PEG) esters 
of fatty acids, is able to further increase the dissolution rate 
compared with PEG usually used before, probably owing to its 
SME property33. Other lipid-based excipients evaluated for 
melt granulation to create solid SMES include lecithin, partial 
glycerides, or polysorbates. The melt granulation process was 
usually used for adsorbing SMES (lipids, surfactants, and 
drugs) onto solid neutral carriers (mainly silica and 
magnesium alumina meta silicate) 34, 35. 
Melt extrusion/extrusion Spheronization: 
Melt extrusion is a solvent-free process that allows high drug 
loading (60%), as well as content uniformity. Extrusion is a 
procedure of converting a raw material with plastic properties 
into a product of uniform shape and density, by forcing it 
through a die under controlled temperature, product flow, and 
pressure conditions 36. The size of the extruder aperture will 
determine the approximate size of the resulting spheroids. The 
extrusion-spheronization process is commonly used in the 
pharmaceutical industry to make uniformly sized spheroids 
(pellets). The extrusion spheronization process requires the 
following steps: Dry mixing of the active ingredients and 
excipients to achieve a homogeneous powder; wet massing 
with binder; extrusion into a spaghetti-like extrudate; 
spheronization from the extrudate to spheroids of uniform 
size; drying; sifting to achieve the desired size distribution and 
coating (optional). In the wet masses comprising SMES 
(Polysorbate 80 and mono-/di-glycerides), lactose, water and 
MCC, the relative quantities of SMES and water had a 
significant effect on the extrusion force, size spread, 
disintegration time, and surface roughness of pellets. Studies 
suggested that the maximum quantity of this SMES that can 
be solidified by extrusion spheronization occupies 42% of the 
dry pellet weight37. Generally, the higher the water level, the 
longer the disintegration time37. The rheological properties of 
wet masses may be measured by an extrusion capillary. It has 
been shown that SMES containing wet mass with a wide range 
of rheological characteristics can be processed, but a single 
rheological parameter cannot be used to provide complete 
characterization of how well it can be processed by extrusion-
spheronization 38. Applying extrusion-spheronization, SME 
pellets of diazepam and progesterone and bi-layered cohesive 
SME pellets have been prepared39, 40. 
Dosage form development of S-SMEDDS: 
Self-emulsifying capsules: After administration of capsules 
containing conventional liquid SE formulations, micro 
emulsion droplets form and subsequently disperse in the GI 
tract to reach sites of absorption. However, if irreversible 
phase separation of the micro emulsion occurs, an 
improvement of drug absorption cannot be expected. For 
handling this problem, sodium dodecyl sulfate was added into 
the SE formulation41. With the similar purpose, the super 
saturable SMEDDS was designed, using a small quantity of 
hydroxyl propyl methyl cellulose (or other polymers) in the 
formulation to prevent precipitation of the drug by generating 
and maintaining a supersaturated state in vivo. This system 
contains a reduced amount of a surfactant, thereby minimizing 
GI side effect42, 43. 
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Self-emulsifying suppositories: Kim and Ku 
(2000) investigated the Solid-SEDDS could increase not only 
GI adsorption but also rectal/vaginal adsorption. Glycyrrhizin 
which by the oral route, barely achieves therapeutic plasma 
concentrations, can obtain satisfactory therapeutic levels for 
chronic hepatic diseases by either vaginal or rectal SE 
suppositories. The formulation included glycyrrhizin and a 
mixture of a C6-C18 fatty acid glycerol ester and a C6-
C18 fatty acid macrogol ester44, 45. 
Self-emulsifying nanoparticles: Nanoparticle techniques 
have been useful in the production of SE nanoparticles. 
Solvent injection is one of these techniques. In this method, 
the lipid, surfactant and drugs were melted together and 
injected drop wise into a stirred non-solvent. The resulting SE 
nanoparticles were thereafter filtered out and dried. This 
approach yielded nanoparticles (about 100 nm) with a high 
drug loading efficiency of 74%46. More recently, a novel 
nanoparticle drug delivery system consisting of chitosan and 
Glyceryl Monooleate (GMO) for the delivery of Paclitaxel 
(PTX) has been developed. The SE property of GMO 
enhanced the solubility of PTX and provided a foundation for 
chitosan aggregation, meanwhile causing near 100% loading 
and entrapment efficiencies of PTX47. 
Self-emulsifying sustained/controlled-release pellets:  
Pellets, as a multiple unit dosage form, possess many 
advantages over conventional solid dosage forms, such as 
flexibility of manufacture, reducing intrasubject and 
intersubject variability of plasma profiles and minimizing GI 
irritation without lowering drug bioavailability48. Thus, it is 
very appealing to combine the advantages of pellets with those 
of SMEDDS by self micron-emulsifying pellets. 
CONCLUSION 
S-SMEDDS are a promising approach for the formulation of 
drugs with poor aqueous solubility. The oral delivery of 
lipophilic drugs can be made possible by S-SMEDDS, which 
have been shown to substantially improve oral bioavailability. 
As mentioned above, numerous studies have confirmed that S-
SMEDDS substantially improved solubility/dissolution, 
absorption and bioavailability of poorly water-soluble drugs. 
As improvements or alternatives of conventional liquid 
SMEDDS, S-SMEDDS are superior in reducing production 
cost, simplifying industrial manufacture, and improving 
stability as well as patient compliance. Most importantly, S-
SMEDDS are very flexible to develop various solid dosage 
forms for oral and parenteral administration. Moreover, GI 
irritation is avoidable and controlled/sustained release of drug 
is achievable. 
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